Form D · Biotechnology
Dyne Therapeutics, Inc.
Waltham, MA · CIK 0001818794
Offering snapshot reported Aug 14, 2020 · SEC filing
- Reported sold
- $116M Offering amount: $116M
- Investors reported
- 19 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 7, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 14, 2020 | Initial | $115,699,984 | No comparison | 19 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-373216
Source: Form D, filed Aug 14, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Oxana Beskrovnaya, Ph.D. | Executive |
| Joshua Brumm | Director, Executive |
| Edward Hurwitz | Director |
| Dirk Kersten | Director |
| Lawrence Klein, Ph.D. | Director |
| David Lubner | Director |
| Jonathan Mc Neill, M.D. | Executive |
| Jason Rhodes | Director |
| Richard Scalzo | Executive |
| Catherine Stehman Breen, M.D. | Director |
| Romesh Subramanian, Ph.D. | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
830 Winter Street
Waltham, MA, 02451
Waltham, MA, 02451